Replies to post #4567 on GTC Biotherapeutics (fka GTCB)

[acgood]

I think the question was in regard to the financial terms of the partnership.

Here is the detail from the 10-k filing:

ATryn ® : We have established a collaboration agreement with LEO for further development and commercialization of ATryn ® in Europe, Canada, and the Middle East. LEO has selected disseminated intravascular coagulation, or DIC, associated with severe sepsis as an acquired antithrombin deficiency indication for development in Europe. LEO has obtained scientific advice from the European Medicines Agency, or EMEA, on the design of a Phase II dose ranging study of approximately 200 patients. Initial clinical sites are opening, and we anticipate patient enrollment lasting 12 months and results being available in mid-2008. We will have the right to use the Phase II data in the U.S. and all other territories outside of LEO’s territories. LEO plans to seek further advice from the EMEA for a potential Phase III study once the Phase II data is available. We will supply the product for these clinical studies and receive payment for delivery of the material to LEO. We will receive a transfer price and royalties on commercial sales of ATryn ® by LEO.

[voodoo in my basemen]

Thanks Dew,
yes before " feb. 2006 "

<<I do not understand your question. Please clarify.>>

Would not suppose it's a mere reciproce question about the size of the pocket.
Other aspects (OK maybe way out) such as linking your name to a new production platform could form a barrier as there will be contracts between b.e. Novo Nordisk/Wyeth and the blood plasma industry.
So what could form a hurdle (excuse me for the direct way of formulating) as the advantages are more or less clear.

Partnering isn't a cake walk evidently, it seems to be quite difficult. I'd like to gain some insight that's all.
V.